Imbio PHA (4.0.0) vs Lung Density Analysis
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if your primary need is rapid, AI-powered assessment of cardiac structures from CT pulmonary angiogram (CTPA) scans to evaluate for right ventricular dilation. This tool is ideal for aiding in the diagnosis and risk stratification of acute conditions like pulmonary embolism and hypertension by providing automated RV/LV and PA/Ao ratio calculations.
View Imbio PHA (4.0.0) →Choose Lung Density Analysis if…
Choose IMBIO's Lung Density Analysis if you require comprehensive quantitative analysis and 3D visualization of lung conditions from CT scans, particularly for chronic diseases such as COPD and emphysema. This solution is best suited for detailed assessment of emphysema, air-trapping, and overall lung density, including support for low-dose CT scans and patient counseling for smoking cessation.
View Lung Density Analysis →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | Lung Density Analysis |
|---|---|---|
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TieBoth tools are designed for high usability, emphasizing fully automated workflows and seamless integration with existing PACS and radiology reporting systems like Nuance PowerScribe. They aim to provide rapid results directly into the patient study, minimizing user intervention and workflow friction.
Clinical Value
Lung Density AnalysisWhile both tools offer significant clinical value in their specialized areas and are FDA-cleared, Tool B (Lung Density Analysis) demonstrates a broader impact. Its validation for low-dose CT scans in lung cancer screening programs and the integration of a patient-centered LungMapu2122 report for smoking cessation counseling address major public health initiatives and enhance patient management beyond just diagnosis.
Pricing & Value
TieBoth tools explicitly state 'contact for pricing' and do not publicly disclose any pricing details. This lack of transparency makes it impossible to conduct a head-to-head comparison of their cost-effectiveness or overall value proposition. Without specific pricing information, a definitive winner cannot be determined.
Enterprise Readiness
Lung Density AnalysisBoth tools are FDA-cleared, HIPAA compliant, and offer cloud and on-premise deployment. However, Tool B (Lung Density Analysis) provides a wider array of deployment options, including local virtualization (VM, Docker), AI marketplace/distribution platforms, and stand-alone web-based access. Its explicit integration with major platforms like Nuance AI Marketplace and GE Health Cloud, and availability through numerous channel partners, indicates superior flexibility and readiness for diverse enterprise environments.
Innovation
Lung Density AnalysisBoth tools leverage AI for automated quantitative image analysis, which is inherently innovative. However, Tool B (Lung Density Analysis) demonstrates greater innovation through specialized features like Imbio Noise Reduction Technology (NRT) for low-dose CT scans, advanced functional mapping of lung conditions, and the patient-centered LungMapu2122 report for smoking cessation counseling. These features extend beyond basic quantification to enhance image quality, provide deeper insights, and facilitate patient engagement.
Support & Docs
TieAs both tools are products of the same company, Imbio, it is reasonable to assume they benefit from consistent corporate support infrastructure and documentation standards. Both have publicly available user manuals, but specific details regarding support channels, response times, or the comprehensive nature of documentation beyond the existence of these manuals are not provided for either tool.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | Lung Density Analysis |
|---|---|---|
| Name | Imbio PHA (4.0.0) | Lung Density Analysis |
| Description | FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | AI-driven medical imaging software that provides quantitative analysis and 3D visualization of lung conditions from CT scans, aiding in the diagnosis and management of diseases like COPD and emphysema. It offers automated workflows and detailed reports for personalized patient care. |
| Company | Imbio | IMBIO |
| Primary Specialties | Cardiology, Pulmonology, Radiology | Pulmonology, Radiology |
| Key Features (Examples) | Automated measurement of right and left ventricle diameters; Calculates RV/LV and PA/Ao ratios; Generates annotated DICOM images and PDF reports. | Automated detection, visualization, and quantification of emphysema; Validated for low-dose CT scans; Mapping of normal lung, air-trapping, and emphysema; Quantitative reports with visuals and bar charts. |
| Target Conditions/Diseases | Pulmonary embolism and hypertension (assessment of right ventricular dilation) | COPD, emphysema, asthma, BOS |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and Lung Density Analysis.